BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakai Y, Isayama H, Sasaki T, Takahara N, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D. A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer. Cancer Chemother Pharmacol. 2013;72:1291-1297. [PMID: 24121456 DOI: 10.1007/s00280-013-2313-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, Zureikat AH, Bahary N, Zeh HJ 3rd. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21:4351-4358. [PMID: 25092157 DOI: 10.1245/s10434-014-3842-z] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 13.0] [Reference Citation Analysis]
2 Imaoka H, Mizuno N, Hara K, Hijioka S, Tajika M, Tanaka T, Ishihara M, Hirayama Y, Hieda N, Yoshida T, Okuno N, Shimizu Y, Niwa Y, Yamao K. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Pancreatology. 2016;16:859-864. [PMID: 27256641 DOI: 10.1016/j.pan.2016.05.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
3 Kan M, Imaoka H, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Umemoto K, Kimura G, Suzuki Y, Eguchi H, Otsuru T, Goda K, Ikeda M. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study. Cancer Chemother Pharmacol 2020;86:203-10. [PMID: 32632515 DOI: 10.1007/s00280-020-04110-3] [Reference Citation Analysis]
4 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
5 Imaoka H, Shimizu Y, Senda Y, Natsume S, Mizuno N, Hara K, Hijioka S, Hieda N, Tajika M, Tanaka T, Ishihara M, Niwa Y, Yamao K. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Pancreatology 2016;16:658-64. [PMID: 27178104 DOI: 10.1016/j.pan.2016.04.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
6 Fu N, Qin K, Li J, Jin J, Jiang Y, Deng X, Shen B. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant chemotherapy timing. Cancer Med 2022. [PMID: 35434972 DOI: 10.1002/cam4.4698] [Reference Citation Analysis]
7 Huang T, Jiang SW, Qin L, Senkowski C, Lyle C, Terry K, Brower S, Chen H, Glasgow W, Wei Y, Li J. Expression and diagnostic value of HE4 in pancreatic adenocarcinoma. Int J Mol Sci 2015;16:2956-70. [PMID: 25642754 DOI: 10.3390/ijms16022956] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
8 Shi S, Yu X. Selecting chemotherapy for pancreatic cancer: Far away or so close? Semin Oncol 2019;46:39-47. [PMID: 30611527 DOI: 10.1053/j.seminoncol.2018.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zhang B, Hong CQ, Luo YH, Wei LF, Luo Y, Peng YH, Xu YW. Prognostic value of IGFBP2 in various cancers: a systematic review and meta-analysis. Cancer Med 2022. [PMID: 35546443 DOI: 10.1002/cam4.4680] [Reference Citation Analysis]
10 Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer 2021;1875:188409. [PMID: 32827580 DOI: 10.1016/j.bbcan.2020.188409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
11 Takahara N, Nakai Y, Isayama H, Sasaki T, Saito K, Noguchi K, Suzuki T, Nakamura T, Sato T, Ishigaki K, Hakuta R, Takeda T, Uchino R, Mizuno S, Kogure H, Tada M, Koike K. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer. Cancer Chemother Pharmacol 2017;80:1105-12. [PMID: 29038848 DOI: 10.1007/s00280-017-3456-9] [Reference Citation Analysis]